![](Market Outlook 06_12_2019_files\bg2.png)
News Analysis
Mankind Pharma eyes acquisition of biotech firms, plans new
launches
Mankind Pharma is looking for buyouts in the biotechnology space after talks with
Bharat Serums and Vaccines fell through. The firm feels a manufacturing site
would be crucial for its biotechnology business and is open to inorganic acquisition
in this space. It is also all set to launch a synthetic female hormone product — the
first Indian firm and the second globally, after Abbott. The acute therapy-focused
company has recently shifted its focus to chronic therapy areas like diabetes and
cardiac ailments. It is also driving 5 per cent of its turnover towards research and
development (R&D). The bulk of the R&D cost is towards biosimilars.
However, Mankind, a Rs 5,600-crore firm, is also keen to launch products in
the biotechnology space and is open to inorganic acquisition in the segment. “For
the biotechnology segment, we are open to inorganic growth. We are looking to
acquire a suitable target that would bring in brands, as well as manufacturing
sites. We plan to launch biotech products in the infertility segment. We were in
talks with Bharat Serums, but the talks fell through,” said R C Juneja, founder and
chairman of Mankind Pharma.
Economic and Political News
RBI's policy surprise: Pause on rate cuts may hit real estate, auto sectors
India's manufacturing capacity utilisation declines to the lowest ever
RBI keeps repo rate unchanged at 5.15%, stance stays accommodative
Corporate News
Fixed deposit holders of debt-laden DHFL asked to submit claims by Dec 17
Tata Motors to set up regional stockyards to ensure car delivery in 3 days
Mankind Pharma eyes acquisition of biotech firms, plans new launches
Govt moves NCLAT against NCLT order making MCA party in all IBC cases